[{"id":"5c9805aa-f9a6-41fd-96e7-7f8d0f28c893","acronym":"","url":"https://clinicaltrials.gov/study/NCT05533697","created_at":"2022-09-09T15:55:01.162Z","updated_at":"2024-07-02T16:35:07.372Z","phase":"Phase 1/2","brief_title":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05533697","lead_sponsor":"ModernaTX, Inc.","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • mRNA-4359"],"overall_status":"Recruiting","enrollment":" Enrollment 194","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 12/08/2027","primary_completion_date":" 12/08/2027","study_txt":" Completion: 12/08/2027","study_completion_date":" 12/08/2027","last_update_posted":"2024-04-26"}]